A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD

This trial is testing the safety and effectiveness of HL231, a new inhaled medication, in people of Chinese ethnicity with moderate to severe chronic obstructive pulmonary disease (COPD). **You may be eligible if...** - You are of Chinese ethnicity and at least 40 years old - You have been diagnosed with moderate to severe COPD confirmed by breathing tests - Your lung function tests show a significantly reduced FEV1 (air you can forcefully exhale in 1 second) - You experience significant breathlessness (mMRC score of at least 2) **You may NOT be eligible if...** - You have asthma, alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, or certain other lung diseases - You have a history of serious heart disease, uncontrolled diabetes, or narrow-angle glaucoma - You have been hospitalized for COPD or pneumonia in the past 8 weeks - You have had a respiratory infection in the past 4 weeks - You are allergic to anticholinergic inhalers, beta-agonists, or related medicines Talk to your doctor to see if this trial is right for you.